written by reader Biotech Insider Alert

By johnl49, January 3, 2015

Touting a $4 Stock with $28M in sales that has a new drug in Phase trials for Uveitis – eye disease. It has been granted ”Orphan Status” by FDA and Phase trial data is due out very soon. ?What is the stock and is this real? He wants $1950 for one year subscription to the newsletter.

This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.

guest

12345

This site uses Akismet to reduce spam. Learn how your comment data is processed.

5 Comments
Inline Feedbacks
View all comments
jerryt1
Member
jerryt1
January 3, 2015 3:25 pm

Am interested also in learning about the company being promoted by Biotech Insider Alert because of a potential Uveitis cure.

Add a Topic
585
👍 6
Randy
Guest
Randy
January 4, 2015 1:34 am
Reply to  jerryt1

I don’t know anything about the company but I do believe it is http://www.xoma.com

modernrock
Irregular
January 5, 2015 1:41 pm
Reply to  Randy

It is indeed XOMA and is old rehash previously covered by SGS

👍 236
Altaf
Guest
January 4, 2015 9:14 am

It seems a biotech drug from blue blood may change the science for cancer cure. No one knows what the drug name yet. If you keep an eye of publications they may cite this drug any time in future.

Add a Topic
3397
👍 17870